This guidance document provides critical recommendations for clinicians managing infections caused by antimicrobial-resistant Gram-negative bacteria commonly encountered in U.S. hospitals. It specifically addresses extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa). These infections pose significant morbidity and mortality risks, often leading to confusion in antibiotic treatment decisions. The document aims to standardize and improve treatment strategies for these challenging resistant pathogens, offering clear diagnostic and therapeutic pathways. It highlights the urgent need for updated clinical protocols to combat the rising threat of antimicrobial resistance effectively.
Key note: Effective management of antimicrobial-resistant Gram-negative infections requires clear, evidence-based guidance to improve patient outcomes and combat rising resistance.